Evidence map›Paper›PMID 37377589›Full record

SynthesisWorld journal of gastroenterology2023

Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis.

Gowthami Sai Kogilathota Jagirdhar, Rakhtan K Qasba, Harsha Pattnaik, Kaanthi Rama, Akshat Banga, Shiva Teja Reddy, Anna Carolina Flumignan Bucharles, Rahul Kashyap, Praveen Reddy Elmati, Vikas Bansal and 3 more

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Gowthami Sai Kogilathota JagirdharDepartment of Medicine, Saint Michaels Medical Center, Newark, NJ 07102, United States.
Rakhtan K QasbaDepartment of Medicine, Green Life Medical College and Hospital, Dhaka 1205, Bangladesh.
Harsha PattnaikDepartment of Medicine, Lady Hardinge Medical College, New Delhi 110001, India.
Kaanthi RamaDepartment of Medicine, Gandhi Medical College, Telangana 500003, India.
Akshat BangaDepartment of Medicine, Sawai Man Singh Medical College, Jaipur 302004, Rajistan, India.
Shiva Teja ReddyDepartment of Medicine, Gandhi Medical College, Telangana 500003, India.
Anna Carolina Flumignan BucharlesDepartment of Medicine, Universidade Positivo, Curitiba 81290-000, PR, Brazil.
Rahul KashyapResearch, WellSpan Health, York, PA 17403, United States.
Praveen Reddy ElmatiDepartment of Interventional Pain Medicine, University of Louisville, Louisville, KY 40292, United States.
Vikas BansalDepartment of Internal Medicine, Mayo Clinic, Rochester, MN 55902, United States.
Yatinder BainsDepartment of Gastroenterology, Saint Michaels Medical Center, Newark, NJ 07102, United States.
Theodore DaCostaDepartment of Gastroenterology, Saint Michaels Medical Center, Newark, NJ 07102, United States.
Salim SuraniDepartment of Medicine, Texas A&M University, College Station, TX 77843, United States. srsurani@hotmail.com.
Dhaka Medical College and Hospital · BDLady Hardinge Medical College · INWinnMed · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) and metabolic-associated fatty liver disease (MAFLD) are on the rise like any other liver disease, and tend to affect 25% of the United States population. The impact of NAFLD and MAFLD on patients with coronavirus disease 2019 (COVID-19) remains unclear.

aimTo identify the association of NAFLD and MAFLD with mortality, hospitalization, hospital length of stay, and supplemental oxygen utilization in COVID-19 patients.

methodsA systematic review of literature on Cochrane, Embase, PubMed, ScienceDirect, and Web of Science databases was conducted from January 2019 to July 2022. Studies that evaluated NAFLD/MAFLD using laboratory methods, noninvasive imaging, or liver biopsy were included. The study protocol was registered in PROSPERO (ID CRD42022313259) and PRISMA guidelines were followed. The National Institutes of Health quality assessment tool was used to assess the quality of the studies. Pooled analysis was conducted using software Rev Man version 5.3. The stability of the results was assessed using sensitivity analysis.

resultsThirty-two studies with 43388 patients were included in the meta-analysis of whom 8538 (20%) patients were observed to have NAFLD. There were 42254 patients from 28 studies included in the mortality analysis. A total of 2008 patients died from COVID-19; 837 (10.52%) in the NAFLD group and 1171 (3.41%) in the non-NAFLD group. The odds ratio (OR) was 1.38 for mortality with a 95% confidence interval (95%CI) = 0.97-1.95 and

conclusionOur meta-analysis suggests that there are increased odds of hospitalization, longer hospital length of stay, and increased use of supplemental oxygen in NAFLD/MAFLD patients.

Indexed as

COVID-19Non-alcoholic Fatty Liver DiseaseBiopsyDatabases, FactualHumansOxygenOxygenCoronavirusCOVID-19Fatty liverMetabolic-associated fatty liverNon-alcoholic fatty liver

Identifiers

PMID37377589
PMCPMC10292144
OpenAlexW4381277968

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.